Erratum to clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma
Erratum to: Transl Lung Cancer Res 2022;11:420-31
This article (1) titled “Clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma” (doi: 10.21037/tlcr-22-190), unfortunately contains an error in the primary affiliation for Haimiao Xu and Guoping Cheng. The current affiliation 8 should be the primary affiliation for Haimiao Xu and Guoping Cheng. Therefore, a superscript “*” should be added to the 8th affiliation for explanation.
The corrected author info is as follows:
Xiaoling Xu1,2#, Wenming Shen3#, Ding Wang2,4#, Na Li5, Zhiyu Huang1,2, Jiamin Sheng1,2, A. Justin Rucker6, Weimin Mao2,7, Haimiao Xu2,8, Guoping Cheng2,8
1Department of Thoracic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; 2Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China; 3Department of Cardiothoracic Surgery, Ningbo Yinzhou No. 2 Hospital, Ningbo, China; 4The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China; 5Shaoxing No. 2 Hospital Medical Community General Hospital, Shaoxing, China; 6Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA; 7Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (lung and esophagus), Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; 8Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China*
Contributions: (I) Conception and design: G Cheng, H Xu, W Mao; (II) Administrative support: X Xu, W Shen; (III) Provision of study materials or patients: N Li, Z Huang; (IV) Collection and assembly of data: D Wang, X Xu; (V) Data analysis and interpretation: X Xu, J Sheng; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
#These authors contributed equally to this work and should be considered as co-first authors.
*The current affiliation 8 should be the primary affiliation for Haimiao Xu and Guoping Cheng.
Correspondence to: Guoping Cheng; Haimiao Xu; Weimin Mao. The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China. Email: chengguoping1218@163.com; xuhm@zjcc.org.cn; maowm1318@163.com.
The authors apologize for the oversight.
Click here to view the updated version of the article.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Xu X, Shen W, Wang D, et al. Clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma. Transl Lung Cancer Res 2022;11:420-31. [Crossref] [PubMed]
